

## Supplementary Figure legends

### Supplementary Figure 1

#### **TNF- $\alpha$ pre-treated endothelial cells bind sCD177/PR3 specifically via PECAM-1.**


- (A)** HUVECs pre-treated with PBS were incubated with saline, rCD177, rPR3 or sCD177/PR3 (2 $\mu$ g/mL) for 4 hours at 37°C. HUVECs were analyzed by flow cytometry using direct fluorescence-labeled mabs against CD177 (MEM166) or PR3 (PR3D1). Values are presented as mean fluorescence intensity (MFI)  $\pm$ SD (n=5); n.s. not significant.
- (B)** HUVECs pre-treated with TNF- $\alpha$  were incubated with rCD177, rPR3 or sCD177/PR3 (2 $\mu$ g/mL) for 4 hours at 37°C. HUVECs were analyzed by flow cytometry using direct fluorescence-labeled mabs against CD177 (MEM166) or PR3 (PR3D1).
- (C)** HUVECs pre-treated with TNF- $\alpha$  were incubated with mabs (1  $\mu$ g/mL), against PECAM-1 domain 1 (Gi18) or against PECAM domains 2 and 6 (PECAM 1.1 or PECAM 1.2, respectively), and subsequently incubated with sCD177/PR3 (2 $\mu$ g/mL) for 4 hours at 37°C. HUVECs were analyzed by flow cytometry using direct fluorescence-labeled anti-CD177 (MEM166).

### Supplementary Figure 2


#### **CD177 expression on neutrophil surface**

Gating strategy (upper) and expression (lower) of CD177 on granulocyte populations. The expression of CD177 on surface of isolated neutrophils were evaluated in CD177-negative (left) and CD177-positive (right) donors using direct fluorescence-labelled mab against CD177 (MEM166, red) in flow cytometry (red). mIgG was used as isotype control (black). The P2 and P3 are representative of the percentage of negative and positive neutrophil sub-populations in each donor.


Supplementary Figure 1A



Supplementary Figure 1B




# Supplementary Figure 1C



# Supplementary Figure 2

A



B

